A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors

• Status: Completed
• Trial end date: 2011-08-29
• Target enrollment: 0
• Participant gender: All

Summary

This clinical study is being conducted at two sites to determine the optimum dose, safety, and tolerability of GSK1363089 treatment in adults with solid tumors. This study is no longer recruiting subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline

Criteria

Inclusion Criteria:

• Histologically confirmed solid tumor which is metastatic or unresectable with no known effective treatment measures,

• ECOG performance status of
• Adequate bone marrow reserve, hepatic, renal, and cardiovascular function,

• Negative pregnancy test.

Exclusion Criteria:

• Chemotherapy within 4-6 weeks of the start of treatment,

• Radiotherapy within 4 weeks of the start of treatment,

• Known brain metastasis,

• Uncontrolled medical disorder such as infection or cardiovascular disease,

• HIV positive,

• Pregnant or breastfeeding women